Last week's news about Pfizer working with Zenith on breast cancer candidate ZEN-3694 got me to thinking.  Why wasn't similar done with Apabetalone? 

At this point I'm assuming it makes zero sense, not this close to the finish line.  But I was recalling a point made in that 'The Street' article about the so called Feurstein-Ratain rule about cancer drugs in phase 3.  Right near the end of the article is this quote:

The market for good cancer drugs is very competitive, when a small-cap company advances a drug on its own into phase III studies, investors should see a red flag. 

I know its for cancer drugs, but I don't think its that much of a stretech to ask the same question of a Phase 3 CVD drug.  I'm also wondering if that is something that may have kept (and may still be keeping) Bio-Tech investors away from Resverlogix.  I'm recalling something SanFran posted a coulple years back (or more) about mentioning Resverlogix to others who expressed a similar sentiment, something along the lines of, "if Apabetalone had any real potential a BP player would have climbed on board or bought them out".  

Pfizer seems like a prime candidate....not only are they working with sister company Zenith, we also know they filed a patent for a treatment of Friedrich's Ataxia that includes Apabetalone.  Obviously that suggests they don't have a problem with Resverlogix/Zenith's team, and it seems they see potential for 208.

Could Shenzhen Hepalink's involvement possibly have kept Pfizer and other BP players at bay?  

Just some thoughts that have been rattling away in my brain as we wait for more substantial news....hopefully this coming week.